How can I use disease-area therapeutic landscape reports to compare oncology and immunology strategies?

Disease-area therapeutic landscape reports are most useful when you use them as a structured comparison tool, not just as a background summary. To compare oncology and immunology strategies, focus on the same set of dimensions in both reports and then align the outputs side by side.

1) Use a common comparison framework

Extract the same categories from each report:

• Disease burden / unmet need
• Standard of care and treatment gaps
• Mechanism of action trends
• Pipeline depth and maturity
• Key modalities
  • small molecules
  • biologics
  • cell/gene therapies
  • antibodies / bispecifics
  • RNA / targeted delivery, etc.
• Biomarkers and patient stratification
• Competitive intensity
• Regulatory and reimbursement environment
• Clinical endpoints and trial design norms
• Commercial opportunity and growth drivers

This lets you compare strategy rather than just compare diseases.

2) Compare the “strategy logic” of each therapeutic area

Oncology

Typically emphasizes:

• Precision medicine
• Tumor-specific biomarkers
• Combination regimens
• Accelerated approvals based on surrogate endpoints
• High innovation density and rapid differentiation

Strategic questions:

• Is the opportunity in a specific tumor subtype or biomarker-defined population?
• Can the product be positioned as a monotherapy, combo partner, or maintenance therapy?
• How crowded is the mechanism class?

Immunology

Typically emphasizes:

• Chronic disease management
• Long-term safety and tolerability
• Durable efficacy
• Broad vs. stratified patient populations
• Switching and sequencing among established biologics

Strategic questions:

• Is the target disease primarily autoimmune, inflammatory, or allergic?
• Is the product aiming for disease modification, symptom control, or steroid-sparing?
• Does the strategy rely on chronic dosing and adherence?

3) Compare pipeline patterns

Look for:

• Number of assets by phase: early, mid, late, approved
• Target concentration: are many assets going after the same target?
• Modal shift: are both areas moving toward bispecifics, cell therapies, etc.?
• Innovation whitespace: where few competitors are active

Common pattern:

• Oncology often has faster cycling and more target crowding.
• Immunology often has more emphasis on platform durability and safety.

4) Compare evidence and endpoint requirements

This is a major strategic differentiator.

Oncology reports usually highlight:

• Objective response rate
• Progression-free survival
• Overall survival
• Minimal residual disease in some settings

Immunology reports usually highlight:

• Clinical remission/response scores
• Flare reduction
• Steroid sparing
• Biomarker shifts
• Quality-of-life and long-term safety

If you’re evaluating a portfolio, ask:

• Which area has easier-to-demonstrate value in trials?
• Which requires longer follow-up?
• Which endpoint is more commercially persuasive?

5) Compare market access and economics

Use the reports to assess:

• Pricing power
• Payer scrutiny
• Duration of therapy
• Patient prevalence and incidence
• Treatment line positioning

General rule:

• Oncology may support high prices per course but often faces intense evidence scrutiny and competitive sequencing.
• Immunology may support recurring revenue through chronic use, but access depends heavily on payer management and real-world differentiation.

6) Compare risk profiles

Build a side-by-side matrix:

Dimension	Oncology	Immunology
Biology complexity	High	High
Trial success rate	Often lower in early development	Variable, but chronic safety matters more
Competitive pressure	Very high	High, especially in mature classes
Commercial stickiness	Can be strong if differentiated	Can be strong with chronic adherence
Regulatory pathway	Often faster in high unmet need	Usually more standard, longer evidence horizon

7) Turn report insights into strategic questions

For each area, ask:

• Where is the strongest unmet need?
• Which mechanisms are becoming crowded?
• Which subpopulations are most commercially attractive?
• Where is the regulatory path most favorable?
• What is the likely time to differentiation?
• Which area aligns better with our company’s capabilities?

8) Build a simple scoring model

You can score both areas on a 1–5 scale for:

• Unmet need
• Competitive intensity
• Differentiation potential
• Probability of technical success
• Time to market
• Commercial attractiveness
• Fit with internal capabilities

Then weight the scores based on your strategy.

9) Watch for report-specific signals

Good therapeutic landscape reports often contain:

• Pipeline maps
• Target heat maps
• Recent clinical readouts
• Partnership/M&A activity
• Patent expiry or exclusivity cliffs
• Biomarker adoption trends
• Geographic differences in uptake

These signals help you understand where strategy is moving, not just where the market is today.

10) Best practice: compare at the indication level, not just the disease area

“Oncology” and “immunology” are very broad. Compare:

• NSCLC vs. rheumatoid arthritis
• Breast cancer vs. IBD
• Hematologic malignancies vs. psoriasis

That gives you a much more meaningful strategic comparison.

---

If you want, I can also give you:

1. a one-page comparison template, or
2. a scoring matrix example for oncology vs. immunology.